Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan

Diabetes Research and Clinical Practice

Volumn 76, Issue 2, 2007, Pages 229-235

  Kawamori, Ryuzo ^a   Kadowaki, Takashi ^b   Onji, Morikazu ^c   Seino, Yutaka ^d   Akanuma, Yasuo ^e  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KANSAI ELECTRIC POWER CO   (Japan)

^e INSTITUTE FOR ADULT DISEASES   (Japan)

Author keywords

Alanine aminotransferase; Hemoglobin A1c; Pioglitazone; Practical; Type 2 diabetes mellitus

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; GLINIDE; HEMOGLOBIN A1C; IMMUNOREACTIVE INSULIN; INSULIN; PIOGLITAZONE; SULFONYLUREA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY DISEASE; HUMAN; INSULIN TREATMENT; JAPAN; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIVER; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 33947107876     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.08.017     Document Type: Article

References (23)

1. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diab. Care 28 (2005) 1547-1554
2. Lawrence J.M., Reid J., Taylor G.J., Stirling C., and Reckless J.P. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diab. Care 27 (2004) 41-46
3. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366 (2005) 1279-1289
4. Kawamori R., Kadowaki T., Onji M., Seino Y., and Akanuma Y. Interim Analysis on PRACTICAL (PRospective ACTos practICAL experience) Study: Efficacy and Safety in Over 20,000 Japanese Type 2 Diabetes Patients. 64th American Diabetes Association. June, Orland, Florida (2004) 4-8
5. Kawamori R., Kadowaki T., Onji M., Seino Y., and Akanuma Y. PRACTICAL (PRospective ACTos practICAL experience) Study: Updated Efficacy and Safety in 23,000 Japanese Type 2 Diabetes Patients. 65th American Diabetes Association. June, San Diego, California (2005) 10-14
6. Robert T.O. In: Karl E.P. (Ed). Biopharmaceutical Statistics for Drug Development (1988), Marcel Dekker, New York, US 543-604
7. Watkins P.B., and Whitcomb R.W. Hepatic dysfunction associated with troglitazone. N. Engl. J. Med. 338 (1998) 916-917
8. Takeda Pharmaceuticals America, Inc., Actos (Pioglitazone Hydrochloride) Tablets, Prescribing Information, Lincolnshire, US, 2000.
9. Graham D.J., Drinkard C.R., and Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am. J. Gastroenterol. 98 (2003) 175-179
10. Belcher G., and Schernthaner G. Changes in liver tests during 1-year treatment of patients with type 2 diabetes with pioglitazone, metformin or gliclazide. Diab. Med. 22 (2005) 973-979
11. Belcher G., Lambert C., Edwards G., Urquhart R., and Matthews D.R. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diab. Res. Clin. Pract. 70 (2005) 53-62
12. Targher G., Bertolini L., Poli F., Rodella S., Scala L., Tessari R., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54 (2005) 3541-3546
13. Bajaj M., Suraamornkul S., Pratipanawatr T., Hardies L.J., Pratipanawatr W., Glass L., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003) 1364-1370
14. Promrat K., Lutchman G., Uwaifo G.I., Freedman R.J., Soza A., Heller T., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
15. Charbonnel B., Matthews D.R., Schernthaner G., Hanefeld M., and on behalf of the QUARTET Study Group. A long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diab. Med. 22 (2004) 399-405
16. Schernthaner G., Matthews D.R., Charbonnel B., Hanefeld M., Brunetti P., and on behalf of the QUARTET Study Group. Efficacy and safety of pioglitazone versus metformin: a double-blind, randomized trial. J. Clin. Endcr. Metab. 89 (2004) 6068-6076
17. Takeda Pharmaceuticals, Co., Actos (Pioglitazone Hydrochloride) Tablets, Prescribing Information, Osaka, Japan, 2006.
18. Data from the Annual Japanese Health, Labour and Welfare Statistics (Monograph), Health and Statistics Association, Ministry of Health, Labour and Welfare, Tokyo, Japan, 2002.
19. Kadowaki T., Miyake Y., Hagura R., Akanuma Y., Kajinuma H., Kuzuya N., et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 26 (1984) 44-49
20. Sone H., Mizuno S., Fujii H., Yoshimura Y., Yamasaki Y., Ishibashi S., et al. Japan Diabetes Complications Study: Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in Asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diab. Care 28 (2005) 1463-1471
21. Fukushima M., Usami M., Ikeda M., Nakai Y., Taniguchi A., Seino Y., et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 53 (2004) 831-835
22. Torrens J.I., Skurnick J., Davidow A.L., Korenman S.G., Santoro N., Soto-Greene M., et al. Ethnic differences in insulin sensitivity and beta-cell function in premenopausal or early perimenopausal women without diabetes: the Study of Women's Health Across the Nation (SWAN). Diab. Care 27 (2004) 354-361
23. Kanauchi M., Nakajima M., Saito Y., and Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. Metabolism 52 (2003) 476-481